<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03262272</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMODAL 2016-A01122-49</org_study_id>
    <nct_id>NCT03262272</nct_id>
  </id_info>
  <brief_title>Evaluation of Biocompatibility and Performances of 4 Dialyzers in Different Mode Treatments</brief_title>
  <acronym>BIOMODAL</acronym>
  <official_title>Evaluation of Dialyzers' Biocompatibility and Performances Compared in Different Dialysis Treatments : Conventional Hemodialysis and Post-dilution Hemodialfiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicenter randomized cross-over study Number of patients : 32 (8 patients per
      group) Obtain objectives data to advise each hemodialyzer according to dialysis treatment and
      patient profile.

      To evaluate the different hemodialyzers and judge their extraction performances in HD and
      post HDF.

      Evaluation of the biocompatibility of the hemodialyzers and the patients' inflammatory
      status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical devices studied :

        -  Leoceed 21HX, hemodialyzer, High permeability PS membrane 2,1 m² , made by Nx Stage in
           Germany

        -  Polypure 22S, hemodialyzer, High permeability PS membrane 2,2 m² , made by Allmed in
           Germany

        -  VIE 21A hemodialyzer, High permeability PS membrane 2,1 m² coated in vitamin E, made by
           Asahi Kasei Medical in Japan

        -  Rexsys 27H, hemodialyzer , High permeability PES membrane 2,7 m² , made by Medica in
           Italia

      These hemodialyzers are EC marked and are used in their own indications.

      Schema

      Details of the cross-over plan :

      8 patients will be treated successively with the 4 hemodialyzers. Patients will be treated
      with the dialyzer &quot;test&quot; for the two first sessions of the week. During the last dialysis
      session of each week, only their usual dialyzer will be used as wash-out. A randomization
      will define the order of use of the dialyzers in the 4 centers. This order will be identical
      in a center.

      Number of patients :

      32 (8 patients per center (4 centers))

      Duration :

      One week per dialyzer
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">December 21, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective randomized cross-over study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of middle molecules extraction</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>Measurements of β 2 microglobulin (11,8kDa), myoglobin (17kDa), Beta Trace (21kDa), Free immunoglobulin light chains Kappa (23kDa), myostatin (40kDa), glycoprotein orosomucoïd (44kDa)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extraction of uremic toxins</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>Urea
Creatinin
inorganic phosphates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biocompatibility assessment</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>Anaphylatoxins (C3a, C5a) during the session (T0, T15, Tend)
TNF-α and IL-6 (T0 et Tend)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of Nutrition status</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>Quantification of the albumin loss in the used dialysate (1 center) during the middle session of the week for each dialyzer tested per patient, i.e 4 times/patient.
2 analysis modalities will be used: &quot; pull and push &quot; syringe Plastipak BD 50mL or collection of the whole dialysate in a 200 L tank
Dosage Albumin et pre-albumin before dialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handling of the devices</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>- Evaluation of the priming and recovery for each dialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis adequacy evaluation</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>Calculation of KT/V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Session tolerance</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>All secondary troubles will be noted: cramps, nauseas, hypotension…</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters inflammation</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>CRP (mg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters inflammation</measure>
    <time_frame>one week per dialyzer per patient</time_frame>
    <description>- Calcul of PINI = [CRP(mg/l) x Orosomucoïd (mg/l)] / [Albumin(g/l) x Pre-albumin(mg/l)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treated by conventionnal hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodiafiltration post dilution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treated by HDF post-dilution</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VIE A Hemodialyzer</intervention_name>
    <description>polysulfon membrane coated with vitamin E</description>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_label>Hemodiafiltration post dilution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rexsys 27H hemodialyzer</intervention_name>
    <description>polyethersulfon membrane with large surface area : 2,7m²</description>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_label>Hemodiafiltration post dilution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Leoceed 21HX hemodialyzer</intervention_name>
    <description>polyslfon membrane with gamma sterilization</description>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_label>Hemodiafiltration post dilution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polypure 22S+ hemodialyzer</intervention_name>
    <description>polysulfon membrane with steam sterilization</description>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_label>Hemodiafiltration post dilution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with chronic kidney disease dialyzed for at least one month and treated
             with the treatment mode that we will test

          -  Patient using post-dilution HDF mode have to use EuDIAL volume guidelines (20-22L
             minimum)

          -  Patient treated before with high permeability membrane

          -  Patient with vascular access allowing a blood flow rate with a minimum of 300 mL/min

          -  Patient treated with a high surface area dialyzer ≥ 1,8 m²

          -  Patient covered by the social French health organism

          -  Patient informed of the study goals and having signed the informed consent

        Exclusion Criteria:

          -  Patient with a vascular access not allowing a blood flow rate minimum of 300 mL/min

          -  Patient with a fast progressive chronic disease

          -  Patient with an uncontrolled anemia

          -  Patient refusing to sign the informed consent

          -  Pregnant or nursing patient

          -  Pediatric patient

          -  Patient under tutorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Paul CRISTOL, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Paul CRISTOL, Professor</last_name>
    <phone>+33 4 67 33 83 15</phone>
    <email>jp-cristol@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia BARBE</last_name>
    <phone>+33 6 30 17 80 37</phone>
    <email>laetitia.barbe@hemotech.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AIDER-Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Paul Cristol, Professor</last_name>
      <phone>+33 4 67 33 83 15</phone>
      <email>jp-cristol@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laetitia Barbe</last_name>
      <phone>+33 6 30 17 80 37</phone>
      <email>laetitia.barbe@hemotech.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kokubo K, Kurihara Y, Kobayashi K, Tsukao H, Kobayashi H. Evaluation of the Biocompatibility of Dialysis Membranes. Blood Purif. 2015;40(4):293-7. doi: 10.1159/000441576. Epub 2015 Nov 17. Review.</citation>
    <PMID>26656534</PMID>
  </reference>
  <reference>
    <citation>Maduell F, Moreso F, Mora-Macià J, Pons M, Ramos R, Carreras J, Soler J, Torres F; study group ESHOL. ESHOL study reanalysis: All-cause mortality considered by competing risks and time-dependent covariates for renal transplantation. Nefrologia. 2016;36(2):156-63. doi: 10.1016/j.nefro.2015.10.007. Epub 2015 Dec 8. English, Spanish.</citation>
    <PMID>26672890</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

